PL3397273T3 - Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego - Google Patents

Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego

Info

Publication number
PL3397273T3
PL3397273T3 PL16826898T PL16826898T PL3397273T3 PL 3397273 T3 PL3397273 T3 PL 3397273T3 PL 16826898 T PL16826898 T PL 16826898T PL 16826898 T PL16826898 T PL 16826898T PL 3397273 T3 PL3397273 T3 PL 3397273T3
Authority
PL
Poland
Prior art keywords
glucosidase
treatment
acid alpha
pompe disease
augmented
Prior art date
Application number
PL16826898T
Other languages
English (en)
Inventor
Hung V. Do
Richie Khanna
Russell GOTSCHALL
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Priority claimed from PCT/US2016/069243 external-priority patent/WO2017117407A1/en
Publication of PL3397273T3 publication Critical patent/PL3397273T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicinal Preparation (AREA)
PL16826898T 2015-12-30 2016-12-29 Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego PL3397273T3 (pl)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562272890P 2015-12-30 2015-12-30
US201662300479P 2016-02-26 2016-02-26
US201662315412P 2016-03-30 2016-03-30
US201662402454P 2016-09-30 2016-09-30
US201662428867P 2016-12-01 2016-12-01
US201662431791P 2016-12-08 2016-12-08
EP16826898.5A EP3397273B1 (en) 2015-12-30 2016-12-29 Augmented acid alpha-glucosidase for the treatment of pompe disease
PCT/US2016/069243 WO2017117407A1 (en) 2015-12-30 2016-12-29 Augmented acid alpha-glucosidase for the treatment of pompe disease

Publications (1)

Publication Number Publication Date
PL3397273T3 true PL3397273T3 (pl) 2021-12-06

Family

ID=60186557

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16826898T PL3397273T3 (pl) 2015-12-30 2016-12-29 Wzmocniona kwaśna α-glukozydaza do leczenia choroby Pompego
PL21174249.9T PL3957320T3 (pl) 2015-12-30 2016-12-29 Wzmocniona kwaśna alfa-glukozydaza do leczenia choroby Pompego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21174249.9T PL3957320T3 (pl) 2015-12-30 2016-12-29 Wzmocniona kwaśna alfa-glukozydaza do leczenia choroby Pompego

Country Status (15)

Country Link
EP (3) EP3957320B1 (pl)
CN (1) CN108472340A (pl)
CY (1) CY1124637T1 (pl)
DK (2) DK3957320T5 (pl)
ES (2) ES2965190T3 (pl)
FI (1) FI3957320T3 (pl)
HK (1) HK1253014A1 (pl)
HR (2) HRP20231465T1 (pl)
HU (2) HUE054733T2 (pl)
LT (2) LT3397273T (pl)
PL (2) PL3397273T3 (pl)
PT (2) PT3397273T (pl)
RS (2) RS64843B1 (pl)
SI (2) SI3397273T1 (pl)
TW (2) TWI753874B (pl)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
CA2814774C (en) 2003-01-31 2016-03-22 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiency disorders
ATE465250T1 (de) * 2004-02-10 2010-05-15 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
PT3470077T (pt) 2008-02-12 2020-11-30 Amicus Therapeutics Inc Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas
AU2010254092B2 (en) * 2009-05-26 2015-11-12 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
PT2844279T (pt) 2012-05-03 2021-03-11 Amicus Therapeutics Inc Esquema posológico para o tratamento da doença de pompe
WO2014014938A1 (en) 2012-07-17 2014-01-23 Amicus Therapeutics, Inc. Alpha-galactosidase a and 1-deoxygalactonojirimycin co-formulation
PT3201320T (pt) * 2014-09-30 2024-01-12 Amicus Therapeutics Inc Alfa-glucosidase ácida altamente potente com hidratos de carbono intensificados

Also Published As

Publication number Publication date
LT3397273T (lt) 2021-06-25
ES2883844T3 (es) 2021-12-09
EP3957320B1 (en) 2023-08-23
EP3397273B1 (en) 2021-05-19
EP4285902A2 (en) 2023-12-06
EP3957320A1 (en) 2022-02-23
LT3957320T (lt) 2023-12-11
SI3397273T1 (sl) 2021-11-30
DK3957320T5 (da) 2024-08-05
PL3957320T3 (pl) 2024-02-19
HUE054733T2 (hu) 2021-09-28
TWI849380B (zh) 2024-07-21
HK1253014A1 (zh) 2019-06-06
CY1124637T1 (el) 2022-07-22
DK3957320T3 (da) 2023-11-27
DK3397273T3 (da) 2021-08-09
TWI753874B (zh) 2022-02-01
HUE064049T2 (hu) 2024-02-28
CN108472340A (zh) 2018-08-31
PT3397273T (pt) 2021-08-09
EP3397273A1 (en) 2018-11-07
HRP20210894T1 (hr) 2021-07-23
SI3957320T1 (sl) 2024-01-31
PT3957320T (pt) 2023-11-23
RS62212B1 (sr) 2021-09-30
EP4285902A3 (en) 2024-02-21
FI3957320T3 (fi) 2023-11-23
ES2965190T3 (es) 2024-04-11
TW202245831A (zh) 2022-12-01
TW201726163A (zh) 2017-08-01
HRP20231465T1 (hr) 2024-03-01
RS64843B1 (sr) 2023-12-29

Similar Documents

Publication Publication Date Title
IL283837A (en) Improved acid alpha-glucosidase for the treatment of Pompe disease
HK1259458A1 (zh) 用於治療心血管疾病的吉卡賓組合
IL253945B (en) kdm1a inhibitors to treat the disease
GB201500314D0 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
ZA201907552B (en) Recombinant human acid alpha-glucosidase
EP3223809A4 (en) Amino acid compositions for the treatment of symptoms of disease
IL255506A (en) A method for treating a neurological disease
EP3310377A4 (en) Method of treating crohn's disease
GB201515244D0 (en) Treatment of inflammatory disease or condition
EP3362085C0 (en) COMPOSITIONS FOR THE TREATMENT OF DISEASES WITH MUCIN
HK1253014A1 (zh) 用於治療龐貝氏病的增强的酸性α-葡糖苷酶
HK1245146A1 (zh) 尿酸性或痛風性疾病的預防或治療
GB201504413D0 (en) Treatment of disease
AU2015902286A0 (en) Method Of Treating Crohn's Disease
AU2015902358A0 (en) Treatment of inflammatory disease